SVIL and neoplasm: Similar to the results in vitro, combining SVIL‐AS1 knockdown and MK2206 or BYL719 therapy induced a significant reduction in tumor growth compared with that of MK2206 or BYL719 alone in MCF‐10A‐Ras AKT1E17K and KU‐19‐19 xenografts (Figure 5C–H).